Simple: stupid decisions (Grail), launching products too early to drive down the price of the genome. To maintain the current revenue rate, with this reduced cost we needed to sequence over 50% more samples. Sample volume was shrinking, NIH and VC funding down the toilet. Trump and all his BS!
Also.... Changes in management, current management trying to make us like Agilent. Firing some of the most committed people in the org. Putting in leaders who know nothing about genomics.
Change programs which are not fit for purpose - who has heard anything about Pinnacle recently??? No... didn't think so.
It does seem now that we are getting lined up for a buy out, but then who would want to buy this cluster F of a company - the good thing is, that if we are bought out they will fire all the management on day one (hopefully) - I am sure they are feeling resilient so they should be fine
I mean there is so much more, but we all know the story